Test Price
2,800 AED✅ Home Collection Available
DCLRE1C Gene – Severe Combined Immunodeficiency (Athabascan Type) Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Accredited Next‑Generation Sequencing with full gene coverage and copy number variant detection.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post‑test clinical guidance for result interpretation by a Consultant Medical Genetics specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Price: 2,800 AED inclusive of genetic counselling support.
Test Overview & Methodology
This test utilizes Next‑Generation Sequencing to analyze the entire DCLRE1C (Artemis) gene, confirming Severe Combined Immunodeficiency (Athabascan type) with near‑perfect precision. The assay detects single nucleotide variants, small insertions/deletions, and copy number variants across the full coding region and splice sites.
| Feature | Our Test (DHA‑Approved) | Closest Alternative |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity (full gene NGS + CNV detection) | Panel‑based or Sanger sequencing limited to known mutations; lower resolution |
| Method | NGS (Next‑Generation Sequencing) with LC‑MS/MS‑validated enrichment | Conventional Sanger sequencing or targeted array |
| Turnaround Time | 3–4 Weeks (expedited reporting available) | 6–8 Weeks |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specialist, I confirm that the DCLRE1C gene analysis provides definitive molecular confirmation for Severe Combined Immunodeficiency Athabascan type. The result must always be interpreted within the full clinical context, including immunological phenotyping and comprehensive family history. A negative result does not entirely exclude the diagnosis if clinical suspicion remains high. Multidisciplinary input is essential for positive findings."
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not discontinue or alter any prescribed medication without first consulting your treating physician. This genetic test result does not replace the need for ongoing clinical management and pharmacological oversight.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals without clinical suspicion or a family history of SCID; recent blood transfusion may interfere with germline analysis.
- Exclusion: Pregnancy‑related testing must be accompanied by formal genetic counselling referral.
- Red Flag: Active severe infection, respiratory distress, or failure to thrive in an infant — seek emergency care immediately. This test is NOT a substitute for urgent medical evaluation.
- Contact our emergency coordination line via the same WhatsApp number if you are unsure about eligibility.
Patient FAQ & Clinical Guidance
1. What is the DCLRE1C gene test used for?
The DCLRE1C gene test definitively diagnoses Severe Combined Immunodeficiency (Athabascan type) and determines carrier status for informed family planning. It analyzes the Artemis protein pathway essential for V(D)J recombination and DNA repair.
2. How is the sample collected, and what should I expect?
A small peripheral whole blood sample or DNA from a painless buccal swab is collected at your home by our licensed phlebotomist using child‑friendly techniques. The procedure takes approximately 10 minutes and requires no special preparation.
3. How long do results take, and how will I understand them?
Results are available within 3–4 weeks from sample receipt. You will receive a detailed clinical interpretation report prepared by our Consultant Medical Genetics specialist, with complimentary telephonic support to address any follow‑up questions.
UAE Regulatory & Data Privacy Adherence
Legal & Regulatory Compliance Framework
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing all patient genetic data processing, storage, and consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating electronic health records and telemedicine infrastructure.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – ensuring clinical safety, informed consent, and professional accountability for genetic testing.
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) – quality management system for laboratory processes.
Clinical & Logistical Metadata
| Test Name | DCLRE1C Gene – Severe Combined Immunodeficiency (Athabascan Type) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Buccal Swab |
| Methodology Used | Next‑Generation Sequencing (NGS) with Full Gene Coverage + CNV Detection |
| ICD-10-CM Code | D81.2 |
| LOINC Code | 21665-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians